# Chicago Metropolitan Asthma Consortium for severe / exacerbation-prone asthma

> **NIH NIH UG1** · UNIVERSITY OF CHICAGO · 2021 · $426,665

## Abstract

PROJECT SUMMARY
This application from the Chicagoland Metropolitan Asthma Consortium (CMAC) is in response to the RFA
entitled “Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma
(PrecISE) Network”. The Chicago metropolitan area has almost 10 million inhabitants who are racially and eth-
nically diverse. The City of Chicago, which represents about one-third of this population, has an asthma preva-
lence rates in both children and adults exceeding 10% and has one of the highest asthma mortality rates in the
United States. Severe and/or exacerbation prone (S/EP) asthma affects over 10% of asthmatic patients and
accounts for both substantial morbidity and a majority of asthma-related costs. While substantial progress has
been made in helping patients control asthma symptoms, how to use current therapies to target specific phe-
notypes precisely and prevent disease progression, and when and how to change these therapies in the event
of failure, remain unclear. The CMAC includes academic medical center partners: Northwestern University, the
University of Chicago, Lurie Children's Hospital, Rush University, and John H. Stroger Hospital, and an expan-
sive network of Community Partners. The CMAC is uniquely qualified to participate in the PrecISE Network
and contribute to the development and successful completion of the network clinical trials and proof of con-
cept/mechanistic studies. Our key personnel have extensive experience in asthma clinical and translational
research, including studies exploring its pathophysiology, pathogenesis (genetic and environmental factors),
epidemiology and treatment; leadership roles in key research support and CTSA programs at their respective
institutions; successful collaborations together and with multiple institutions and networks on asthma research
programs; access to a large, diverse asthma population; and documented, successful ability to enroll patients
in NIH, foundation and industry sponsored asthma research studies and clinical trials. We propose a model
intervention sequential, adaptive clinical trial protocol with three targeted, precise interventions that will be
guided by repeated assessment of biomarkers to inform both the initial therapy choice and subsequent inter-
ventions. Further, our proposal utilizes the latest adaptive clinical trial design, careful longitudinal follow-up,
and will use the responses of early-recruited patients to guide targeted therapy in subsequently-enrolled sub-
jects. Our targeted interventions include three different anti-cytokine and prostaglandin therapies directed to
Th2-high patients, and three different therapies directed to Th2-low, obese and lean patients. Participation by
the CMAC will strengthen the PrecISE Network so that it will achieve its goal to complete successfully early-
phase clinical trials to test targeted interventions in patients with S/EP asthma, generate new knowledge re-
garding asthma phenotypes, pr...

## Key facts

- **NIH application ID:** 10219341
- **Project number:** 5UG1HL139125-05
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** Sharon R. Rosenberg
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $426,665
- **Award type:** 5
- **Project period:** 2017-09-23 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10219341

## Citation

> US National Institutes of Health, RePORTER application 10219341, Chicago Metropolitan Asthma Consortium for severe / exacerbation-prone asthma (5UG1HL139125-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10219341. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*